MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Mac... (nistration may provide the patient withe...)

MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema

Date:10/1/2007

nistration may provide the patient with exposure to sirolimus for up to approximately three months.

In addition to safety and tolerability data, the study provided an initial assessment of sirolimus' biological activity in DME. At 45 and 90 days following treatment, patients receiving the two lowest doses of sirolimus by subconjunctival injection demonstrated mean improvements in visual acuity of 8.5 and 7.4 letters over baseline, respectively, using a standard (ETDRS) eye chart. Additionally, this group of patients also experienced anatomical improvements, with a mean decrease in foveal thickness that was consistent with the observed functional improvements in visual acuity. Preliminary data for these patients at 180 days following treatment suggest that these initial improvements in visual acuity and foveal thickness reductions were maintained, or even enhanced, over time in many patients.

"The fact that we are seeing measures of biological activity maintained, and, in some cases improving, through 180 days following a single subconjunctival injection, is somewhat surprising. This finding raises the possibility that sirolimus may be fundamentally changing the course of diabetic retinopathy through its impact on the mTOR (mammalian target of rapamycin) pathway rather than simply reversing macular edema in a more non-specific way," said Dr. Blumenkranz. "Further studies to support or refute this hypothesis will be necessary. However, if so, then the potential clinical utilization of the drug may eventually extend beyond those patients with clinically significant diabetic macular edema."

"The study's findings are intriguing, particularly in light of the fact that a majority of the participants had been previously treated for DME. As such, these results provide great excitement for researchers as we prepare to advance this product into Phase 2 clinical studies," stated David A. Weber, Ph.D., president and chief executive officer of MacuSight. "We are
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering. In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering. A portion of the proceeds will ...

(Date:5/23/2013)... -- A recently published clinical study conducted at TOPS Comprehensive ... demonstrates that 3D mammography (breast tomosynthesis) significantly reduces unnecessary ... The study, "Implementation of Breast Tomosynthesis in a Routine ... Stephen L. Rose , MD, and published ... of Roentgenology (AJR). The AJR is the scientific ...

(Date:5/23/2013)... , May 23, 2013 More than half ... not benefit from chemotherapy and still have excellent outcomes. ... of one of the largest sources of online consumer ... and interactive Facebook page provide recently diagnosed women with ... safely avoid chemotherapy. "We anticipate these innovative ...

Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4 First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2 First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3

[0] Nephros Announces Completion of Rights Offering [0] First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams [0] Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions

... Mass. , May 5 LightLab Imaging, ... Optical Coherence Tomography (OCT) technology for vascular and other ... and Drug Administration (FDA) for the C7-XR Imaging System ... LightLab,s latest generation Frequency Domain OCT (FD-OCT™) technology, are ...

... May 5 Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH) ... Care Conference in New York, New York , on May 11, 2010 , ... , , A live ... . The webcast will be archived for replay following the conference. , ...

Cached Medicine Technology:LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 2 LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 3 LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 4 Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference 2

LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference

(Date:5/25/2013)... York (PRWEB) May 25, 2013 ... litigation underway in U.S. District Court, Western District of ... According to a Case Management Order issued on ... the filing of contested motions in the Actos bladder ... motions. (In re: Actos Product Liability Litigation, MDL No. ...

(Date:5/25/2013)... May 25, 2013 Studies from Johns ... are carrying excessive weight and their inability to get ... simply losing weight can naturally relieve many symptoms. ... improvement in sleep quality was significantly associated with overall ... study dated November 6th, 2012, researchers monitored ...

(Date:5/25/2013)... (PRWEB) May 25, 2013 The ... ranging from irritable bowel syndrome (IBS) to bloating, ... among the most long-lasting, embarrassing, frustrating and difficult ... foods for digestive health have provided a ... are many factors contributing to digestive health issues, ...

(Date:5/25/2013)... (PRWEB) May 25, 2013 Dr. Farooq ... surgery clinic in Dubai, has announced his practice’s adoption ... is the only FDA-cleared femtosecond laser proven with more ... safety and precision of LASIK. , “We are happy ... Advanced Femtosecond Laser at our Dubai LASIK practice,” Ashraf ...

(Date:5/25/2013)... Prairie Living at Chautauqua , ... American Red Cross Blood Drive from 1:30 to 5:30 ... is located at 955 Villa Ct. in Carbondale, Illinois, ... Medicaid, who need some help to maintain their independence.. ... Andrea Arview Frey, Director of Marketing for Prairie Living. ...

Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2 Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3 Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2 Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2 Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2 Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2

[0] Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation [0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep [0] Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org [0] Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method [0] Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive

... New York Health AdvisoryNEW YORK, Feb. 12 Asthma ... in New York City, according to the United States ... suggests that there are many causes for asthma attacks, ... system changes that result from the presence, or lack ...

... Non-attorney Representation Services , ... Belleville, Ill. (PRWEB) February ... can increase their changes of getting awarded when they hire representation, ... the Social Security Disability Insurance (SSDI) process each year. ...

... doctors, nurses, and other medical personnel wear scrubs in the ... and ties to work. What we wear, as we ... comfortable, all the while maintaining our professionalism. With all ... someone go about making an important decision such as which ...

... has been enormous public controversy over the piece published ... stimulus bill. Betsy McCaughey, Ph.D. states:1) While ... Coordinator of Health Information Technology was created by former ... for doctors and hospitals that voluntarily adopted electronic medical ...

... RUTHERFORD, N.J., Feb. 11 Cambrex Corporation (NYSE: CBM ... period ended December 31, 2008., , ... quarter 2007 and full year sales decreased 3.7% excluding the impact ... for the quarter and year, respectively. , ...

... and MTA: CTIC) announced today that the Borsa Italiana, ... Company,s common stock on the MTA stock,market in Milan, ... on February 10th. As a result of the ... additionally been halted on the NASDAQ Stock Market,pursuant to ...

Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma Social Security Disability Applicants Increase Chances for Benefits with Representation So Many Nursing Scrubs, So Many Decisions: blue sky scrubs Offers Tips on How to Find That Perfect Set of Medical Scrubs Betsy McCaughey Responds to Poorly Informed Critics Cambrex Reports Fourth Quarter and Full Year 2008 Results Cell Therapeutics Updates Shareholders on Trading

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Pb, Urine Parvovirus B19 Antibody, IgM Parvovirus B19 Antibodies, IgG & IgM Partial Thromboplastin Time with Reflex to PTT 1:1 Mix